Equal Weight ETF Outperforms S&P 500 for Over Two Decades, Poised for Further Growth

Ramit Sethi

Author of "I Will Teach You to Be Rich," focusing on psychology and systems for a rich life without guilt.

For more than two decades, an investment vehicle has consistently delivered superior returns compared to the widely followed S&P 500 index. This particular exchange-traded fund (ETF) allocates an equivalent weighting to each of its constituent companies, a strategy that has proven more advantageous over time. With recent market dynamics, this equal-weighted approach appears ready for another period of strong performance.

The Enduring Appeal of Equal Weighting in a Shifting Market

Invesco's S&P 500 Equal Weight ETF (RSP) presents a compelling alternative to the traditional S&P 500 index. While both funds comprise the same companies, their weighting methodologies diverge significantly. The standard S&P 500 assigns greater importance to companies with larger market capitalizations, meaning a select few giants can heavily influence its overall performance. For instance, a dominant player like Nvidia constitutes a substantial portion of the S&P 500, whereas in the RSP, its allocation is comparable to any other company within the fund, typically around 0.2%.

Historically, this equal distribution has been a key factor in RSP's ability to surpass the S&P 500's returns for much of the last two decades. The traditional index only began to narrow this performance gap recently, largely due to the extraordinary surge of a few mega-cap technology firms. When these high-growth companies experience rapid appreciation, they naturally elevate the entire market-cap-weighted index.

However, this reliance on a handful of top performers also introduces vulnerability. A downturn in these highly weighted companies can disproportionately drag down the entire S&P 500. A prime example is the "Magnificent Seven" — Apple, Alphabet, Amazon, Meta Platforms, Microsoft, Nvidia, and Tesla — which collectively represent approximately one-third of the S&P 500's total valuation. In recent weeks, concerns over AI expenditure have led to a noticeable decline in these tech behemoths. The Roundhill Magnificent Seven ETF, which focuses solely on these seven stocks, has experienced a dip exceeding 13% in the past month. Conversely, the remaining companies in the S&P 500, excluding these seven, actually saw a rise of over 2.5% during the same period. Yet, the concentrated influence of the mega-cap tech sector meant the broader S&P 500 still registered a slight decline.

It is precisely in such market environments that the Invesco S&P 500 Equal Weight ETF shines. For investors seeking a more diversified exposure and wary of the outsized impact of a few tech giants, this ETF offers a strategic advantage. While past performance does not guarantee future results, the current market dynamics suggest that RSP could widen its outperformance if the tech sector continues to face headwinds, offering a potentially more stable and rewarding investment path.

The market's current state, marked by a recalibration away from hyper-growth tech stocks, underscores the value of diversification. The success of the Invesco S&P 500 Equal Weight ETF serves as a powerful reminder that a balanced portfolio, where every component has an equitable opportunity to contribute, can often lead to more resilient and potentially superior long-term returns. Investors are encouraged to consider how such a strategy aligns with their financial objectives and risk tolerance in an evolving economic landscape.

you may like

youmaylikeicon
Jade Biosciences: A Promising Contender in the IgA Nephropathy Market

Jade Biosciences: A Promising Contender in the IgA Nephropathy Market

By Ramit Sethi
Teledyne Technologies Reports Strong Q1 Organic Growth, Attracting Investor Attention Amid Market Shifts

Teledyne Technologies Reports Strong Q1 Organic Growth, Attracting Investor Attention Amid Market Shifts

By Dave Ramsey
Contrarian Investment Strategies for Retirement: A Detailed Review of Envista, MSG Entertainment, and Smucker

Contrarian Investment Strategies for Retirement: A Detailed Review of Envista, MSG Entertainment, and Smucker

By Mr. Money Mustache
Cooke Acquires Mowi's East Canadian Salmon Farms

Cooke Acquires Mowi's East Canadian Salmon Farms

By Mr. Money Mustache
German Beverage Industry Opposes Proposed Sugar Tax

German Beverage Industry Opposes Proposed Sugar Tax

By Natalie Pace
Akebia Therapeutics Reinforces Vafseo Patent Portfolio

Akebia Therapeutics Reinforces Vafseo Patent Portfolio

By Natalie Pace
Syndax Pharmaceuticals: A Biotech Opportunity Amidst Evolving AML Market Dynamics

Syndax Pharmaceuticals: A Biotech Opportunity Amidst Evolving AML Market Dynamics

By Scott Pape
MapLight Therapeutics: A Biotech Stock to Watch

MapLight Therapeutics: A Biotech Stock to Watch

By JL Collins
Takeda's Pharmaceutical Innovations: Growth Prospects Amidst Promising Clinical Trial Results and Regulatory Milestones

Takeda's Pharmaceutical Innovations: Growth Prospects Amidst Promising Clinical Trial Results and Regulatory Milestones

By Natalie Pace
BeOne Medicines AG: Advancements in Cancer Treatment and Market Outlook

BeOne Medicines AG: Advancements in Cancer Treatment and Market Outlook

By Vicki Robin
Tyra Biosciences (TYRA): A Promising Biotech Investment Opportunity Amidst Key Trial Data Anticipation?

Tyra Biosciences (TYRA): A Promising Biotech Investment Opportunity Amidst Key Trial Data Anticipation?

By Vicki Robin
BridgeBio Oncology: A Promising Horizon in Cancer Treatment with KRAS G12C

BridgeBio Oncology: A Promising Horizon in Cancer Treatment with KRAS G12C

By JL Collins
Organon's Strategic Expansion in Women's Health and Biosimilars

Organon's Strategic Expansion in Women's Health and Biosimilars

By JL Collins
La Doria Acquires Solana to Bolster Tomato Product Portfolio

La Doria Acquires Solana to Bolster Tomato Product Portfolio

By JL Collins
Celldex Therapeutics: Growth Prospects and Barzolvolimab's Potential Approval

Celldex Therapeutics: Growth Prospects and Barzolvolimab's Potential Approval

By T. Harv Eker